

49th WHO EXPERT COMMITTEE ON DRUG DEPENDENCE

Provisional Agenda

Information Meeting (Virtual)

19 October 2026

10:00-13:00 CEST

1. Welcome and opening of the meeting

2. WHO presentations

- 2.1 Expert Committee on Drug Dependence
- 2.2 Science Division
- 2.3 Gender, Equity, and Human Rights
- 2.4 Legal and Ethics

3. Presentations and statements from participants



49th WHO EXPERT COMMITTEE ON DRUG DEPENDENCE

Geneva, Switzerland

Provisional Agenda

Closed Session

19-22 October 2026

1. Procedural matters and updates

- 1.1 Opening of meeting and welcoming remarks
- 1.2 Introduction of participants
- 1.3 Statement of confidentiality
- 1.4 Declarations of interest
- 1.5 Election of Chair, Vice-Chair, and Rapporteur
- 1.6 Adoption of agenda

2. Updates on priorities from international agencies

- 2.1 Briefings from international agencies on their work on the public health dimension of the world drug problem
 - 2.1.1 WHO
 - 2.1.2 UNODC
 - 2.1.3 INCB
- 2.2 Updates on ECDD meeting recommendations and outcomes
 - 2.2.1 Recommendations and outcomes of the 48th ECDD
 - 2.2.2 Updates on substance surveillance

3. Critical reviews: Recommendations on the scope of international control

- 3.1 Cychlorphine / N-propionitrile chlorphine – critical review (Opioids)
- 3.2 Desalkylgidazepam – critical review (Benzodiazepine)
- 3.3 Ethylbromazolam – critical review (Benzodiazepine)
- 3.4 Etomidate – Pre-review (medicine anaesthetic)
- 3.5 Medetomidine – Pre Review (veterinary medicine - anaesthetic)
- 3.6 Etomethazene (5-methyl etodesnitazene) (Opioids)
- 3.7 Spirochlorphine (Opioids)
- 3.8 Clobromazolam (Benzodiazepines)

4. Finalization of meeting report